Sinotherapeutics Inc. (688247.SH): The cooperative product Enzalutamide tablets have been approved by the National Medical Products Administration.

Sinotherapeutics Inc. (688247.SH) announced that recently, the company's jointly developed Enzalutamide tablets have received the Drug Registration Certificate issued by the National Medical Products Administration, approving the listing of Enzalutamide tablets. Enzalutamide is a type of androgen receptor inhibitor. The approved indications for this drug include: use in adult patients with metastatic hormone-sensitive prostate cancer (mHSPC); adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis; and the treatment of adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or have mild symptoms after androgen deprivation therapy (ADT) failure and have not received chemotherapy. In addition, this product received temporary approval from the U.S. Food and Drug Administration in June 2025.